• BioRelix Inc., of New Haven, Conn., completed a $27.8 million Series A round led by CHL Medical Partners. The company expects to use those funds to build a portfolio of anti-infective product candidates based on bacterial RNA targets called RiboSwitches. The financing is anticipated to support an investigational new drug application with at least one RiboSwitch class and advance other compounds targeting different classes through late-stage preclinical development. BioRelix expects to have a CEO in place by early fall. Additional investors in the Series A were New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. Philippe Chambon, of NLV Partners, Dov Goldstein, of Aisling, and Campbell Murray, of Novartis Venture Fund, joined BioRelix's board.

• Boston Life Sciences Inc., of Hopkinton, Mass., changed its name to Alseres Pharmaceuticals Inc. and begins trading under its new stock symbol "ALSE" today. The name change is intended to reflect the company's transformation from a life sciences firm to one with a biopharmaceutical focus. Alseres is developing Altropane, a Phase III-stage molecular imaging agent for diagnosing Parkinson's disease, and Cethrin, a recombinant protein-based drug designed to promote nerve repair after acute spinal cord injury.

• Resverlogix Corp., of Calgary, Alberta, closed a previously announced $25 million sale of 8 percent senior secured convertible promissory notes due June 6, 2012. The notes are convertible into about 1.5 million common shares at C$17.50 per share. Buyers also got warrants to purchase 529,350 shares at C$20.63 per share. Oppenheimer & Co. Inc. was placement agent for the deal.